Centroblastic diffuse large B cell lymphoma displays distinct expression pattern and prognostic role of apoptosis resistance related proteins

Cancer Invest. 2012 Jun;30(5):404-14. doi: 10.3109/07357907.2012.672844.

Abstract

Centroblastic diffuse large B cell lymphoma (DLBCL) samples were analyzed by immunohistochemistry to evaluate the expression of p53, Bcl-2, Survivin, XIAP, and Ki-67. Survivin was the only protein which expression exhibited a trend for impact in progression-free (p = .077) and overall survival (p = .054). In the Mann-Whitney test, Survivin expression correlated with a negative overall survival (p = .045). These results appeared to be intimately related to Survivin cytoplasmic localization. Moreover, the anti-apoptotic proteins Bcl-2 and Survivin were less frequent in centroblastic DLBCL. Our results indicate that centroblastic DLBCL may be a disease with characteristic biology and clinical course and, therefore, specific prognostic factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Apoptosis*
  • Humans
  • Inhibitor of Apoptosis Proteins / analysis
  • Ki-67 Antigen / analysis
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / pathology*
  • Middle Aged
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2 / analysis
  • Survivin
  • Tumor Suppressor Protein p53 / analysis
  • X-Linked Inhibitor of Apoptosis Protein / analysis

Substances

  • BIRC5 protein, human
  • Inhibitor of Apoptosis Proteins
  • Ki-67 Antigen
  • Proto-Oncogene Proteins c-bcl-2
  • Survivin
  • Tumor Suppressor Protein p53
  • X-Linked Inhibitor of Apoptosis Protein
  • XIAP protein, human